Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review)
- Authors:
- Feng Jiao
- Ziliang Jin
- Lei Wang
- Liwei Wang
-
Affiliations: Department of Oncology, The First People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 201620, P.R. China - Published online on: August 20, 2013 https://doi.org/10.3892/br.2013.158
- Pages: 819-827
This article is mentioned in:
Abstract
|
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar | |
|
Ebert MP, Schandl L and Malfertheiner P: Helicobacter pylori infection and molecular changes in gastric carcinogenesis. J Gastroenterol. 37(Suppl 13): 45–49. 2002. View Article : Google Scholar | |
|
Krejs GJ: Gastric cancer: epidemiology and risk factors. Dig Dis. 28:600–603. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nagini S: Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng L, Wang L, Ajani J and Xie K: Molecular basis of gastric cancer development and progression. Gastric Cancer. 7:61–77. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Remo A, Pancione M, Zanella C and Vendraminelli R: Molecular pathology of colorectal carcinoma. A systemic review centred on the new role of the pathologist. Pathologica. 104:432–441. 2012.PubMed/NCBI | |
|
Zayakin P, Ancans G, Silina K, et al: Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer. 132:137–147. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lu H, Goodell V and Disis ML: Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 7:1388–1394. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Grotowski M: Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer. Pol Merkur Lekarski. 12:77–80. 2002.(In Polish). | |
|
Takahashi Y: Gastrointestinal cancer. Gan To Kagaku Ryoho. 31:1275–1279. 2004.(In Japanese). | |
|
Park IJ, Choi GS and Jun SH: Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer. Anticancer Res. 29:4303–4308. 2009.PubMed/NCBI | |
|
Fernandes LL, Martins LC, Nagashima CA, Nagae AC, Waisberg DR and Waisberg J: CA72-4 antigen levels in serum and peritoneal washing in gastric cancer. Correlation with morphological aspects of neoplasia. Arq Gastroenterol. 44:235–239. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H and Haglund C: CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 22:2311–2316. 2002.PubMed/NCBI | |
|
Chen XZ, Zhang WK, Yang K, et al: Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep. 39:9031–9039. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, Kohne CH, Lang I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011. | |
|
Joyce T, Oikonomou E, Kosmidou V, et al: A molecular signature for oncogenic BRAF in human colon cancer cells is revealed by microarray analysis. Curr Cancer Drug Targets. 12:873–898. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee J, Seo JW, Jun HJ, et al: Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 25:1517–1524. 2011. | |
|
Bayrak M, Olmez OF, Kurt E, et al: Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer. Clin Transl Oncol. 15:307–312. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong J, Zhao M, Ma Y, et al: UCHL1 acts as a colorectal cancer oncogene via activation of the β-catenin/TCF pathway through its deubiquitinating activity. Int J Mol Med. 30:430–436. 2012.PubMed/NCBI | |
|
Bellini MF, Cadamuro AC, Succi M, Proenca MA and Silva AE: Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012:8919612012. View Article : Google Scholar : PubMed/NCBI | |
|
Fang Z, Xiong Y, Li J, et al: APC gene deletions in gastric adenocarcinomas in a Chinese population: a correlation with tumour progression. Clin Transl Oncol. 14:60–65. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu CP, Kao TY, Chang WL, Nieh S, Wang HL and Chung YC: Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol. 37:140–147. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tate G, Suzuki T, Nemoto H, Kishimoto K, Hibi K and Mitsuya T: Allelic loss of the PTEN gene and mutation of the TP53 gene in choriocarcinoma arising from gastric adenocarcinoma: analysis of loss of heterozygosity in two male patients with extragonadal choriocarcinoma. Cancer Genet Cytogenet. 193:104–108. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K and Moustafa A: Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis. 20:19–24. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Toh Y, Oki E, Oda S, et al: Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer. 74:459–463. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Du B, Yang ZY, Zhong XY, et al: Metastasis-associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer. World J Gastroenterol. 17:1219–1226. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oliveira LA, Artigiani-Neto R, Waisberg DR, Fernandes LC, de Lima FO and Waisberg J: NM23 protein expression in colorectal carcinoma using TMA (tissue microarray): association with metastases and survival. Arq Gastroenterol. 47:361–367. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tahara E, Kuniyasu H, Nakayama H, Yasui W and Yokozaki H: Metastasis related genes and malignancy in human esophageal, gastric and colorectal cancers. Gan To Kagaku Ryoho. 20:326–331. 1993.(In Japanese). | |
|
Li N, Wang HX, Zhang J, Ye YP and He GY: KISS-1 inhibits the proliferation and invasion of gastric carcinoma cells. World J Gastroenterol. 18:1827–1833. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng HC, Yu AM and Xin Y: Aberrant expression of Kiss-1 and matrix metalloproteinase-9 are closely linked to lymph node metastasis of gastric cancer. Chin Med Sci J. 23:63–64. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ilhan O, Celik SY, Han U and Onal B: Use of KAI-1 as a prognostic factor in gastric carcinoma. Eur J Gastroenterol Hepatol. 21:1369–1372. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW and Barrett JC: Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res. 59:5724–5731. 1999.PubMed/NCBI | |
|
Lee JH, Seo YW, Park SR, Kim YJ and Kim KK: Expression of a splice variant of KAI1, a tumor metastasis suppressor gene, influences tumor invasion and progression. Cancer Res. 63:7247–7255. 2003.PubMed/NCBI | |
|
Hu H, Sun L, Guo C, et al: Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res. 15:5485–5493. 2009. View Article : Google Scholar | |
|
Liu C, Xue H, Lu Y and Chi B: Stem cell gene Girdin: a potential early liver metastasis predictor of colorectal cancer. Mol Biol Rep. 39:8717–8722. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chang W, Ma L, Lin L, et al: Identification of novel hub genes associated with liver metastasis of gastric cancer. Int J Cancer. 125:2844–2853. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bai FH, Wang NJ, Wang J, et al: Screening and identification of peritoneal metastasis-related genes of gastric adenocarcinoma using a cDNA microarray. Genet Mol Res. 11:1682–1689. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liang B, Wang S, Yang X, Ye Y, Yu Y and Cui Z: Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer. Chin Med J (Engl). 116:20–23. 2003.PubMed/NCBI | |
|
Choi MG, Noh JH, An JY, et al: Expression levels of cyclin G2, but not cyclin E, correlate with gastric cancer progression. J Surg Res. 157:168–174. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kouraklis G, Katsoulis IE, Theocharis S, et al: Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? Dig Dis Sci. 54:1015–1020. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ogino S, Nosho K, Irahara N, et al: A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 15:4431–4438. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai HL, Yeh YS, Chang YT, et al: Co-existence of cyclin D1 and vascular endothelial growth factor protein expression is a poor prognostic factor for UICC stage I–III colorectal cancer patients after curative resection. J Surg Oncol. 107:148–154. 2013.PubMed/NCBI | |
|
Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J and Jirstrom K: Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. Biol Sex Differ. 2:102011. View Article : Google Scholar : PubMed/NCBI | |
|
Geng M, Wang L, Cao YC, Li H and Liu XH: Relationship of the expression of cyclin D1 and P21WAF1 with the sensitivity to chemotherapeutic drugs on gastric cancers. Chin J Gastroenterol Surg. 12:615–617. 2009.(In Chinese). | |
|
Li HL, Huang DZ, Deng T, et al: Overexpression of cyclin L2 inhibits growth and enhances chemosensitivity in human gastric cancer cells. Asian Pac J Cancer Prev. 13:1425–1430. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Firestein R, Shima K, Nosho K, et al: CDK8 expression in 470 colorectal cancers in relation to β-catenin activation, other molecular alterations and patient survival. Int J Cancer. 126:2863–2873. 2010.PubMed/NCBI | |
|
Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, et al: Expression of p16INK4a, alone or combined with p53, is predictive of better prognosis in colorectal adenocarcinoma in Tunisian patients. Appl Immunohistochem Mol Morphol. 19:562–568. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang F, Yang YZ, Shi CZ, et al: UHRF1 promotes cell growth and metastasis through repression of p16ink4ain colorectal cancer. Ann Surg Oncol. 19:2753–2762. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nakayama G, Kodera Y, Ohashi N, Koike M, Fujiwara M and Nakao A: p16INK4amethylation in serum as a follow-up marker for recurrence of colorectal cancer. Anticancer Res. 31:1643–1646. 2011. | |
|
Al-Maghrabi J, Al-Ahwal M, Buhmeida A, et al: Expression of cell cycle regulators p21 and p27 as predictors of disease outcome in colorectal carcinoma. J Gastrointest Cancer. 43:279–287. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MY, Han SI and Lim SC: Roles of cyclin-dependent kinase 8 and β-catenin in the oncogenesis and progression of gastric adenocarcinoma. Int J Oncol. 38:1375–1383. 2011. | |
|
Masuda TA, Inoue H, Nishida K, et al: Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res. 9:5693–5698. 2003.PubMed/NCBI | |
|
Sun W, Yao L, Jiang B, Shao H, Zhao Y and Wang Q: A role for Cdkl1 in the development of gastric cancer. Acta Oncol. 51:790–796. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gryko M, Pryczynicz A, Guzinska-Ustymowicz K, et al: Immunohistochemical assessment of apoptosis-associated proteins: p53, Bcl-xL, Bax and Bak in gastric cancer cells in correlation with clinical and pathomorphological factors. Adv Med Sci. 57:77–83. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tsujitani S, Saito H, Wakatsuki T, et al: Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer. Surg Today. 42:225–232. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pietrantonio F, Biondani P, de Braud F, et al: Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. Transl Oncol. 5:155–159. 2012. View Article : Google Scholar | |
|
Jeong SH, Han JH, Kim JH, et al: Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci. 56:131–138. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Cai H, Huang H, Long Z, Shi Y and Wang Y: The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One. 6:e296702011. View Article : Google Scholar : PubMed/NCBI | |
|
Yildirim M, Suren D, Goktas S, et al: The predictive role of Bcl-2 expression in operable locally advanced or metastatic gastric carcinoma. J BUON. 17:106–109. 2012.PubMed/NCBI | |
|
Lee JS, Jung WK, Jeong MH, Yoon TR and Kim HK: Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway. Int J Toxicol. 31:70–77. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MA, Lee HE, Lee HS, Yang HK and Kim WH: Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. Virchows Arch. 459:503–510. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Paschos KA, Canovas D and Bird NC: The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal. 21:665–674. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Paredes J, Figueiredo J, Albergaria A, et al: Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 1826:297–311. 2012.PubMed/NCBI | |
|
Almeida PR, Ferreira VA, Santos CC, et al: E-cadherin immunoexpression patterns in the characterisation of gastric carcinoma histotypes. J Clin Pathol. 63:635–639. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Stanculescu D, Margaritescu C, Stepan A and Mitrut AO: E-cadherin in gastric carcinomas related to histological prognostic parameters. Rom J Morphol Embryol. 52(Suppl 3): 1107–1112. 2011.PubMed/NCBI | |
|
Chen X, Wang Y, Xia H, et al: Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis. Mol Biol Rep. 39:6707–6714. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kang H, Min BS, Lee KY, et al: Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol. 18:711–719. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Okugawa Y, Toiyama Y, Inoue Y, et al: Clinical significance of serum soluble E-cadherin in colorectal carcinoma. J Surg Res. 175:e67–e73. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kamikihara T, Ishigami S, Arigami T, et al: Clinical implications of N-cadherin expression in gastric cancer. Pathol Int. 62:161–166. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MA, Jung EJ, Lee HS, et al: P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance. Hum Pathol. 41:877–885. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Hu H, Peng L, et al: P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. Am J Pathol. 179:380–390. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Park J, Park E, Han SW, et al: Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer. Invest New Drugs. 30:1404–1412. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
St Hill CA: Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci. 16:3233–3251. 2011.PubMed/NCBI | |
|
Ferroni P, Roselli M, Spila A, et al: Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer. 116:2913–2921. 2010. View Article : Google Scholar | |
|
Sato H, Usuda N, Kuroda M, Hashimoto S, Maruta M and Maeda K: Significance of serum concentrations of E-selectin and CA19-9 in the prognosis of colorectal cancer. Jpn J Clin Oncol. 40:1073–1080. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Robertson JH, Yang SY, Winslet MC and Seifalian AM: Functional blocking of specific integrins inhibit colonic cancer migration. Clin Exp Metastasis. 26:769–780. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Alexiou D, Karayiannakis AJ, Syrigos KN, et al: Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients. Am J Gastroenterol. 98:478–485. 2003. View Article : Google Scholar | |
|
Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A and Kemona H: Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb Res. 129:e47–e50. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kuai WX, Wang Q, Yang XZ, Zhao Y, Yu R and Tang XJ: Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol. 18:979–985. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS, Choi I, Ning Y, et al: Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer. 106:1833–1841. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Barderas R, Bartolome RA, Fernandez-Acenero MJ, Torres S and Casal JI: High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. Cancer Res. 72:2780–2790. 2012. | |
|
Formentini A, Braun P, Fricke H, Link KH, Henne-Bruns D and Kornmann M: Expression of interleukin-4 and interleukin-13 and their receptors in colorectal cancer. Int J Colorectal Dis. 27:1369–1376. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liang J, Li Y, Liu X, Xu X and Zhao Y: Relationship between cytokine levels and clinical classification of gastric cancer. Asian Pac J Cancer Prev. 12:1803–1806. 2011.PubMed/NCBI | |
|
Leushacke M, Sporle R, Bernemann C, et al: An RNA interference phenotypic screen identifies a role for FGF signals in colon cancer progression. PLoS One. 6:e233812011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao WM, Wang L, Park H, et al: Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res. 16:5750–5758. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF and Wu CM: CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol. 18:1249–1256. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cambien B, Richard-Fiardo P, Karimdjee BF, et al: CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One. 6:e288422011.PubMed/NCBI | |
|
Chen HJ, Edwards R, Tucci S, et al: Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. J Clin Invest. 122:3184–3196. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Heckmann D, Laufs S, Maier P, et al: A lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion. Onkologie. 34:502–508. 2011.PubMed/NCBI | |
|
Margolin DA, Silinsky J, Grimes C, et al: Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1α/CXCR4 paracrine signaling. Neoplasia. 13:874–886. 2011.PubMed/NCBI | |
|
Skeen VR, Paterson I, Paraskeva C and Williams AC: TGF-β1 signalling, connecting aberrant inflammation and colorectal tumorigenesis. Curr Pharm Des. 18:3874–3888. 2012. | |
|
Ananiev J, Gulubova M, Tchernev G, et al: Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. Wien Klin Wochenschr. 123:668–673. 2011. | |
|
Terashima M, Kitada K, Ochiai A, et al: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 18:5992–6000. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Li Q and Zhu L: Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 98:105–112. 2012.PubMed/NCBI | |
|
Yang X, Takano Y and Zheng HC: The pathobiological features of gastrointestinal cancers (Review). Oncol Lett. 3:961–969. 2012.PubMed/NCBI | |
|
Kim JY, Bae BN, Kwon JE, Kim HJ and Park K: Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma. APMIS. 119:449–459. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai HL, Yang IP, Lin CH, et al: Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection. Int J Colorectal Dis. 28:415–424. 2013. View Article : Google Scholar | |
|
Hasan MR, Ho SH, Owen DA and Tai IT: Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int J Cancer. 129:2115–2123. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Morales-Gutierrez C, Abad-Barahona A, Moreno-Gonzalez E, Enriquez de Salamanca R and Vegh I: Tumour VEGF/non tumour VEGF protein expression ratio as a biomarker for survival in colorectal cancer patients. Eur J Surg Oncol. 37:526–531. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sun P, Yu H, Zhang WQ, Hu M and Lv R: Lentivirus-mediated siRNA targeting VEGF inhibits gastric cancer growth in vivo. Oncol Rep. 28:1687–1692. 2012.PubMed/NCBI | |
|
Li M, Liu F, Sun P, et al: Correlations between serum levels of vascular endothelial growth factor and endostatin with clinical pathological characteristics of patients with gastrointestinal cancers. Hepatogastroenterology. 59:1865–1868. 2012. | |
|
Villarejo-Campos P, Padilla-Valverde D, Martin RM, et al: Serum VEGF and VEGF-C values before surgery and after postoperative treatment in gastric cancer. Clin Transl Oncol. 15:265–270. 2013. View Article : Google Scholar | |
|
Zhou Y, Li N, Zhuang W and Wu X: Vascular endothelial growth factor (VEGF) gene polymorphisms and gastric cancer risk in a Chinese Han population. Mol Carcinog. 50:184–188. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Zhu GY, Gao HY, Zhao SP and Xue Y: Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma. J Surg Oncol. 103:243–247. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kosaka Y, Mimori K, Fukagawa T, et al: Clinical significance of molecular detection of matrix metalloproteinase-1 in bone marrow and peripheral blood in patients with gastric cancer. Ann Surg Oncol. 19(Suppl 3): S430–S437. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lu ZH, Fang YJ, Wu XJ, Pan ZZ and Wan DS: Expression of matrix metalloproteinase 1 in tissue of colon carcinoma and its clinical prognostic significance. Zhonghua Yi Xue Za Zhi. 91:2895–2898. 2011.(In Chinese). | |
|
Noh S, Jung JJ, Jung M, et al: MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology. 58:2015–2019. 2011.PubMed/NCBI | |
|
Kryczka J, Stasiak M, Dziki L, Mik M, Dziki A and Cierniewski C: Matrix metalloproteinase-2 cleavage of the β1 integrin ectodomain facilitates colon cancer cell motility. J Biol Chem. 287:36556–36566. 2012. | |
|
Yang B, Su K, Gao J and Rao Z: Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer. Asian Pac J Cancer Prev. 13:1049–1052. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bi Z, Dong LD and Gu XM: Clinical significance of MMP-7 and PTEN expression in colorectal cancer. Hepatogastroenterology. 60:32–36. 2012.PubMed/NCBI | |
|
Fanelli MF, Chinen LT, Begnami MD, et al: The influence of transforming growth factor-α, cyclooxygenase-2, matrix metalloproteinase (MMP)-7, MMP-9 and CXCR4 proteins involved in epithelial-mesenchymal transition on overall survival of patients with gastric cancer. Histopathology. 61:153–161. 2012. | |
|
Sena P, Mariani F, Marzona L, et al: Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages. Int J Oncol. 41:260–266. 2012.PubMed/NCBI | |
|
Inagaki D, Oshima T, Yoshihara K, et al: Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer. Anticancer Res. 30:4127–4130. 2010.PubMed/NCBI | |
|
Yoshikawa T, Cho H, Tsuburaya A and Kobayashi O: Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer. 12:31–36. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T and Seiki M: Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer. 77(Suppl 8): 1676–1680. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Miyagi M, Aoyagi K, Kato S and Shirouzu K: The TIMP-1 gene transferred through adenovirus mediation shows a suppressive effect on peritoneal metastases from gastric cancer. Int J Clin Oncol. 12:17–24. 2007. View Article : Google Scholar | |
|
Nuovo GJ, Macconnell PB, Simsir A, Valea F and French DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55:267–275. 1995. | |
|
Li BS, Zhao YL, Guo G, et al: Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 7:e416292012. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Li JF, Cai Q, et al: MiRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol. Sep 7–2012.(Epub ahead of print). | |
|
Zhang X, Cui L, Ye G, et al: Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol. 33:2349–2355. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Gu H, Wang S, et al: Circulating miR-17-5p and miR-20a: Molecular markers for gastric cancer. Mol Med Rep. 5:1514–1520. 2012.PubMed/NCBI | |
|
Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al: Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med. 10:1862012. View Article : Google Scholar : PubMed/NCBI | |
|
Kanaan Z, Rai SN, Eichenberger MR, et al: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 256:544–551. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nugent M, Miller N and Kerin MJ: Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 106:947–952. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue T, Iinuma H, Ogawa E, Inaba T and Fukushima R: Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep. 27:1759–1764. 2012.PubMed/NCBI | |
|
Li J, Guo Y, Liang X, et al: MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol. 138:763–774. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu XM, Qian JC, Deng ZL, et al: Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett. 4:339–345. 2012.PubMed/NCBI | |
|
Zhou T, Zhang G, Liu Z, Xia S and Tian H: Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Colorectal Dis. 28:19–24. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hur K, Toiyama Y, Takahashi M, et al: MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. Jul 10–2012.(Epub ahead of print). | |
|
Li CL, Nie H, Wang M, et al: microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep. 27:1960–1966. 2012.PubMed/NCBI | |
|
Li Z, Cao Y, Jie Z, et al: miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett. 323:41–47. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ruzzo A, Graziano F, Vincenzi B, et al: High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy- refractory metastatic disease. Oncologist. 17:823–829. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu K, Liang X, Shen K, et al: MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res. 318:2168–2177. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Osawa S, Shimada Y, Sekine S, et al: MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett. 2:613–619. 2011.PubMed/NCBI |
